Drug intelligence / Profile preview

BSA@CuO-NPs

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems

Overview

BSA@CuO-NPs are bovine serum albumin-coated copper oxide nanoparticles designed as radiosensitizers for cancer treatment, particularly glioblastoma. They are synthesized via carbodiimide crosslinking chemistry using EDC/NHS-mediated activation to covalently attach BSA to the copper oxide nanoparticle surface. The BSA coating enhances biocompatibility, colloidal stability, and cellular uptake while reducing aggregation in physiological environments. These nanoparticles work by enhancing the effects of ionizing radiation through increased DNA damage and apoptosis induction in cancer cells.

Other names: BSA-coated CuO nanoparticlesbovine serum albumin-coated copper oxide nanoparticles

Targets

DNA

Beyond the preview

Go deeper on BSA@CuO-NPs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSA@CuO-NPs.

Explore the full profile